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Abstract
Background: Type 2M von Willebrand disease (VWD2M) is usually characterized by 
VWF:RCo/VWF:Ag<0.6 and normal multimeric profile; desmopressin (DDAVP) chal-
lenge test commonly shows poor response of VWF:RCo.
Objective: We describe the bleeding tendency and the laboratory phenotype in a pa-
tient carrying two heterozygous mutations affecting VWF- A1 domain and VWF- A2 
domain.
Subjects/methods: A 12- year- old patient (O blood group) with severe hemorrhagic 
tendency was phenotypically and genotypically analyzed; his parents were also 
studied.
Results: The proband showed decrease FVIII:C, VWF:RCo/VWF:Ag, and VWF:CB6/
VWF:Ag ratios, but normal platelet count, VWF:CB1/VWF:Ag ratio, VWFpp and mul-
timeric pattern, suggesting a VWD2M phenotype. The DDAVP challenge test, com-
pared to controls (VWD2M patients with mutations in VWF- A1 domain), showed 
lower increase of FVIII:C and VWF:Ag than in heterozygous, but very similar to ho-
mozygous control. Two mutations were found in heterozygous and trans presentation: 
p.Pro1648fs*45 and a novel missense mutation, p.Arg1426Cys. The mother was 
p.Arg1426Cys heterozygous carrier, with few clinical symptoms. The father was 
asymptomatic, with no mutations. The p.Pro1648fs*45 was considered an apparent 
de novo mutation; proband’s AS- PCR revealed mosaicism in the paternal allele. 
According to the predicted models, p.Arg1426Cys would not be affecting the binding 
of GPIbα to A1 domain, whereas p.Pro1648fs*45 seems to modify the folding of A2 
domain, and in this way, it would affect the binding to GPIbα and type VI collagen. We 
believe that the combination of these two heterozygous mutations, in a child with O 
blood group, could result in a defective phenotype enhancer.
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1  | INTRODUCTION
Von Willebrand disease type 2M (VWD2M) is an autosomal domi-
nant bleeding disorder usually described by laboratory phenotype of 
VWF:RCo/VWF:Ag<0.6 and normal multimeric profile. Most cases 
show defective platelet glycoprotein Ibα (GPIbα) binding, revealed by 
low VWF:RCo. Although VWF:CB/VWF:Ag>0.6 are frequent, abnor-
mal ratios are also described.1,2 Mutations responsible for VWD2M 
are mainly clustered in the VWF- A1 domain.
We describe a patient with a severe bleeding score and VWD2M 
laboratory phenotype, in which a compound heterozygous state was 
detected, and his behavior was compared to Caucasian VWD2M con-
trols (heterozygous and homozygous) with mutations in the VWF- A1 
domain.
2  | MATERIALS AND METHODS
2.1 | Subjects and controls
The proband is a Caucasian 12- year- old boy. He was referred due 
to epistaxis requiring tamponades, bleeding after tooth eruption 
and extraction, easy bruising, gum bleeding, and bleeding in the cen-
tral nervous system. After this last episode, he started prophylactic 
treatment with VWF- FVIII concentrates (1000 U, twice a week). The 
bleeding score was calculated according to the ISTH bleeding assess-
ment tool (ISTH- BAT).3 His 30- year- old mother had epistaxis, easy 
bruising, gum bleeding, and abnormal menstrual score according to 
the Pictorial Bleeding Assessment Chart4 (PBAC = 192, nv < 185). His 
40- year- old father and his sister did not show bleeding symptoms. The 
parents were non- consanguineous. They gave their written informed 
consent for the study, in accordance with the declaration of Helsinki. 
Moreover, approval from the Ethics Committee of the Academia 
Nacional de Medicina, Buenos Aires, Argentina, was obtained.
Thirteen VWD2M patients, with desmopressin (DDAVP) challenge 
test, were selected as controls. They carry either homozygous: p.Ar-
g1374Cys (n = 1), or heterozygous mutations: p.Arg1334Gln (n = 1), 
p.Arg1374Leu (n = 1), p.Arg1374Cys (n = 7), p.Ala1437Thr (n = 2), 
p.Thr1468Ile (n = 1).
2.2 | Sample preparation
Peripheral venous blood was drawn in 3.13% sodium citrate for clotting 
tests and in 2% EDTA (disodium ethylenediaminetetraacetate dihydrate) 
for DNA analysis. An anticoagulant with anti- proteases (3.8% sodium 
citrate; 60 mmol/L N- ethylmaleimide, 50 mmol/L EDTA, and 2000 KIU/
mL aprotinine), was used to collect samples for multimer analysis.
2.3 | Laboratory methods
The following tests were performed: blood platelet count (Plt); bleed-
ing time (BT) (Ivy’s method); factor FVIII (FVIII:C) (one- stage)5; VWF 
antigen (VWF:Ag) (ELISA)6; ristocetin cofactor activity (VWF:RCo) 
(aggregometry)7; VWD- collagen binding (VWF:CB1) (ELISA, type 
I collagen); VWF:CB6 (ELISA, type VI collagen); VWF propeptide 
(VWFpp)8 (ELISA); multimer analysis.9 VWF:RCo/VWF:Ag (RCo/Ag), 
VWF:CB1/VWF:Ag (CB1/Ag), VWF:CB6/VWF:Ag (CB6/Ag), and 
VWFpp/VWF:Ag (VWFpp ratio) ratios were calculated.
2.4 | Biologic response to DDAVP
Blood samples for DDAVP challenge test were obtained before and 
90 minutes after the intravenous infusion of DDAVP (0.3 μg/kg body- 
weight during 20 minutes). The time courses of FVIII:C, VWF:Ag, and 
VWF:RCo were analyzed, considering good response when all abnor-
mal parameters reached normal levels.10
Proband’s behavior was compared to controls (11 heterozygous 
VWD2M, mean age of 24.4 ± 14.7- year- old, and 1 homozygous 
patient, aged 7 years); 36% of them had O blood group. BS and BT 
were lower in heterozygous controls (BS: 4.8 ± 3.5; BT: 7.4 ± 1.7 min-
utes) than in the homozygous control (BS: 9; BT: 8 minutes).
2.5 | Genotypic analysis
Genomic DNA was extracted from peripheral blood using standard 
methods. Exons 17, 26 to 31, and 52 of VWF gene were analyzed using 
polymerase chain reaction technique (PCR), and primers designed in 
our laboratory. Both forward and reverse strands were sequenced by 
automated sequencing technology (ABI Prism 310 Genetic Analyzer; 
Applied Biosystems, Foster City, CA, USA). One- hundred random 
healthy controls were also screened.
Allele- specific PCR method (AS- PCR) was developed to establish 
if mutations were located in cis or trans position. To achieve this goal, 
an asymmetric PCR method was optimized. This procedure produced 
ssDNA fragments of 902 base- pairs in a single step when primer pairs 
were used at a 10:1 molar ratio in the presence of genomic DNA. 
 AS- forward primer (AS- 1426- Fw- mut) was designed by using appro-
priate software to allow the PCR amplification only if the nucleotide 
at the 3′- end of the primer complemented the base at the c.4276 
Essentials
• Compound heterozygosity causes a VWD2M phenotype in a child with severe bleeding symptoms.
• p.P1648fs*45 changes the folding of A2 domain altering VWF binding to GPIbα and type VI collagen.
• p.P1648fs*45 was considered as an apparent de novo mutation; AS-PCR revealed paternal mosaicism.
• Bleeding score and DDAVP’s response were worse than those seen in VWD2M heterozygous controls.
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position in the C1426- DNA sample. The PCR reaction tube contained 
2.5 μL genomic DNA as template, 1 μL GoTaq DNA polymerase (5 U/
μL), 10 μL 10× PCR Buffer, 1 μL dNTP (2 mmol/L mix), 1 μL 25 mmol/L 
MgCl2, 1 μL 20 μmol/L AS- forward primer, and 0.1 μL 20 μmol/L 
 28- F- rev as reverse primer.
AS- 1426- Fw- mut: 5′- TGCCAACCTCAAGCAGATCt- 3′.
Primer 28- F- rev: 5′- AAGCCAGGATTAGAACCCGA- 3′, located at 
intron 28.
PCR cycling: initial denaturation (94°C, 5 minutes); 35 cycles: 94°C, 
1 minutes; 63°C, 45 seconds; 72°C, 80 seconds; final extension: 72°C, 
10 minutes. The optimum annealing temperatures were determined 
using a gradient PCR. After the amplification, electrophoresis was per-
formed at 120 V for 30 minutes in 1× tris- borate- EDTA buffer on 2.0% 
agarose gel stained with Sybr- Safe (3 μL). The amplified PCR products 
were visualized under UV light. The forward stand was sequenced.
2.6 | In silico, alignment, and modeling analysis
The in silico analysis of changes was performed using PolyPhen- 2 
(http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.bii.a-star.
edu.sg/), and Mutation Taster (http://www.mutationtaster.org/). The 
potential effect of p.Arg1426Cys on the destabilization of the VWF 
protein was analyzed using the I- mutant 3.0 tool (http://gpcr2.bio-
comp.unibo.it/cgi/predictors/ accessed August 2017).
The alignment was made using CLC sequence viewer (http://www.
clcbio.com) showing part of the wild type VWF and the protein carrying 
both the p.Arg1426Cys in the VWF- A1 domain and p.Pro1648fs*45 
in the VWF- A2 domain. To gain graphical comprehension of the 
interaction between GPIbα and VWF in silico docking simulations 
were performed; X- Ray diffraction- solved structure of the complex 
GPIbα with the A1 domain of wild type VWF (1SQ0)11 was performed. 
Using SwissPDBviewer the arginine1426 of the VWF- A1 domain was 
substituted by cysteine to create the A1 domain with the missense 
mutation p.Arg1426Cys. The VWF- A2 domain was modeled with 
CPH model 3.2 server (www.cbs.dtu.dk) that used the solved crys-
tal structure of the VWF- A2 domain (3ZQK.A) as a template.12 The 
complex structure was obtained using protein- protein docking server 
ClusPro2.0 (http://cluspro.bu.edu)13 and PatchDock- server (http://bio-
info3d.cs.tau.ac.il/PatchDock)14 (Figure 1). The ClusPro prediction was 
preferred over Patchdock prediction as the PDBsum Procheck (http://
www.ebi.ac.uk)15 values were less favorable for the latter. All the mod-
els shown had a Ramachandran plot with 98.9% of the residues within 
the most favored and additionally allowed regions.
2.7 | Statistical analysis
Continuous variables were expressed using mean (X), standard devia-
tion (SD), and minimum (min) and maximum (max) values (ranges).
3  | RESULTS AND DISCUSSION
The phenotypic and the molecular data of the proband and his par-
ents are display in Table 1. Proband’s results suggested a VWD2M 
phenotype, whereas mother’s results revealed a possible type 1 VWD; 
father’s results were normal.
F IGURE  1 Hypothetical model of 
platelet glycoprotein Ib-alpha (GPIbα) 
with the A1 and A2 domains of von 
Willebrand factor (VWF). GPIbα (green) 
with the A1 (red) and A2 (blue) domains 
of VWF are shown: (A) both A1 and A2 
wild type; (B) mutated A1 (p.Arg1426Cys) 
(mutated residue in orange) and A2 wild 
type; (C) wild type A1 and mutated A2 
(p.Pro1648fs*45) (difference with A2 
wild type shown in cyan); (D) mutated 
A1 (p.Arg1426Cys) and mutated A2 
(p.P1648fs*45)
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DDAVP challenge test usually shows poor response of VWF:RCo in 
VWD2M16; however, poor response is not required for VWD2M diag-
nosis. The proband, in addition to the absence of response of VWF:RCo, 
showed FVIII:C, and VWF:Ag that did not reach normal values after 
DDAVP infusion (poor response to DDAVP). The increase of both FVIII:C 
and VWF:Ag was lower than the increase observed in heterozygous 
VWD2M controls. The proband’s DDAVP challenge test showed a sim-
ilar pattern to that seen in the homozygous VWD2M control (Figure 2).
Two mutations, in heterozygous state, were found in the exon 28 
of the VWF in the proband. A novel missense substitution, c.4276C>T 
(NM_000552.4) causing the change of an arginine to cysteine at resi-
due 1426 (p.Arg1426Cys) (NP_000543.2; reference ID: rs555366738) 
in the VWF- A1 domain was detected, in addition to c.4944delT 
(p.Pro1648fs*45) in the VWF- A2 domain. No changes were found in 
exons 17, 26, 27, 29 to 31, and 52, where several type 2M mutations 
have been reported. The mother showed the p.Arg1426Cys in hetero-
zygosity; the father did not show mutations in exon 28.
The novel p.Arg1426Cys was predicted to be deleterious by in 
silico analysis (PolyPhen- 2 score: 0.998; SIFT score: 0.00). I- Mutant 
3.0 predicted a large decrease of VWF stability for p.Arg1426Cys with 
a DDG of −0.73 Kcal/mol. In sequence alignment, this residue was 
shown located in a highly- conserved region in the mammalian spe-
cies compared, confirming the deleterious effect of the mutant. It 
was absent in our 100 healthy controls, therefore, not considered to 
be a polymorphism in our general population. The global minor allele 
frequency (MAF) for the C>T change was 0.0002/1, and validated 
by 1000G Project. The allele frequency informed by ExAC browser 
was 1.648 × 10−5 (2/121386 alleles) (http://exac.broadinstitute.org/ 
Accessed August 2017).
The p.Pro1648fs*45 was found only in the proband, suggesting 
an apparent de novo presentation. The proband’s AS- PCR showed 
the absence of both mutations in the same allele, therefore indicating 
a trans presentation. Considering that the mother only has the p.Ar-
g1426Cys, we assume that the p.Pro1648fs*45 has a paternal ori-
gin, possibly due to mosaicism. It is difficult to discriminate whether 
the mutation occurred at some point during the development of 
the germ line (in his sperm), or postzygotically (somatic mosaicism), 
unless DNA from other tissues (hair roots, urine specimen, buccal 
swap, skin biopsy) were used to see if it is present in his father’s 
somatic cells.17
It has been described2 that several selected VWD2M variants 
showed normal expression as heterozygous recombinant VWF, which 
may not reflect plasma VWF in affected patients; whereas homozy-
gous expression of variants was consistent with VWD2A. This incon-
sistency may result from differences in secretion of VWF, presence 
of other variants or other coagulation defects that could modify the 
phenotype. The type 1 VWD p.Arg1379Cys has been described to 
have a synergistic effect together with p.Ala1377Val (polymorphism 
TABLE  1 Phenotypic and molecular data of the proband and his parents
Patient
Mother Father Normal values
Desmopressin
Pre Post
BS 14 5 0 Males < 3 
Females < 5
Blood group O B A
Plt (×109/L) 220 224 248 160 150- 400
BT (min) 5.5 nd nd nd <4.5
FVIII:C (IU/dL) 24 45 90 115 50- 150
VWF:Ag (IU/dL) 17 34 45 128 50- 150
VWF:RCo (IU/dL) 9 9 46 101 50- 150
RCo/Ag 0.53 0.26 1.01 0.79 >0.6
VWF:CB1 (IU/dL) 17.2 24 nd nd 60- 130
CB1/Ag 1.01 0.71 nd nd >0.6
VWF:CB6 (IU/dL) 4.5 8 nd nd 60- 130
CB6/Ag 0.26 0.24 nd nd >0.6
VWFpp (IU/dL) 27 nd nd nd 50- 150
VWFpp/Ag 1.6 nd nd nd 0.92- 2.14
Multimeric profile Presence of all the multimeric forms nd nd





BS, bleeding score; Plt, platelet count; BT, bleeding time; FVIII:C, factor VIII; VWF:Ag, von Willebrand factor antigen; VWF:RCo, ristocetin cofactor activity; 
RCo/Ag: VWF:RCo/VWF:Ag; VWF:CB1: VWF- type I collagen binding; CB1/Ag: VWF:CB1/VWF:Ag; CB6: VWF- type VI collagen binding; CB6/Ag: 
VWF:CB6/VWF:Ag; ND: not done.
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in ISTH- SSC VWF database), determining a VWD2M.18 This pheno-
type does not appear with p.Ala1377Val alone or with a hypotheti-
cal unidentified third mutation located outside the VWF- A1 domain. 
Other situations in which a second mutation and the O blood group 
reinforces the decrease of FVIII:C and VWF have been reported.19,20
VWF binds types I and III collagen via the VWF- A3 and VWF- A1 
domains, but it binds sub- endothelial type VI collagen exclusively via 
the VWF- A1 domain21; the latter seems to be important in the VWF- 
platelet binding under low shear.22 Reduced binding to type VI colla-
gen has been reported in VWD2M patients in the presence of four 
mutations located in VWF- A1 domain.23
Fidalgo et al.1 described a VWD2M patient with heterozygous 
compound genotype for p.Arg1315Hys associated with type 1 VWD, 
and another mutation in the splicing site c.7464C>T in exon 44, who 
presented reduced RCo/Ag and CB6/Ag, but normal CB1/Ag. The pro-
band has shown similar phenotypic characteristics.
The native state of VWF- A1 domain is highly flexible; platelet 
adhesion under shear flow is highly dependent on it.24 Certain muta-
tions can induce changes in thermodynamic and kinetic stability, 
resulting in the local misfolding of the VWF- A1 domain in secondary 
structures that affects GP1bα binding, and results in loss- of- function 
phenotype (VWD2M).25 The p.Arg1426Cys mutation would not affect 
the binding of GPIbα to VWF- A1 domain, because is not in the zone of 
contact; nevertheless, it could affect the binding to other molecules. 
The p.Pro1648fs*45 determines the position of the VWF- A2 domain, 
close to the leucine rich repeats rather than on the concave part of 
GPIbα as seen in the model obtained with wild type VWF- A2 domain 
interaction. This mutation seems to affect the GPIbα- VWF binding, as 
clashes were found between them which do not appear in the wild 
type VWF- A2 domain. Therefore, this mutation may correspond to a 
misfolding of the VWF- A2 structure, which would affect its function in 
direct or indirect way; it may hinder VWF secretion or function. These 
observations, plus the fact that the in silico result for I- Mutant 3.0 pre-
dicted a large decrease of VWF stability for p.Arg1426Cys, allow us to 
hypothesize that the presence of p.Arg1426Cys and p.Pro1648fs*45 
may cause destabilization of the VWF- A1 domain and misfolding of 
VWF- A2 domain, resulting in the reduced binding of the double- 
mutant to GPIbα and to type VI collagen.
Compound heterozygosity would result in a severe clinical phe-
notype, similar to a homozygous VWD2M behavior, despite it is not 
the case. Heterozygous p.Arg1426Cys in proband’s mother suggests 
possible type 1 VWD, and p.Pro1648fs*45 has been described as 
responsible for type 1 VWD. Therefore, there are some inconsis-
tencies between proband’s genotype and phenotype. The bleeding 
history and the VWD2M laboratory phenotype, including the poor 
response to DDAVP, seen in the proband would be the result of 
a synergistic effect. We believe that the combination of the two 
heterozygous mutations could modify the expression of VWF and 
result in a defective phenotype enhancer, as was described for other 
mutations.2,19,20
ACKNOWLEDGEMENTS
The authors are grateful to Maria Marta Casinelli for her excellent 
technical assistance.
AUTHOR CONTRIBUTIONS
A. I. Woods and M. A. Lazzari were responsible for the study con-
cept and design, analysis of data, and wrote the manuscript. A. I. 
Woods performed VWF:RCo, VWF:CB6, and genotypic assays, 
and was responsible for collecting data. J. Paiva and A. C. Kempfer 
F IGURE  2 Desmopressin (DDAVP) 
challenge test. Comparison of FVIII:C: 
factor VIII; VWF:Ag: von Willebrand factor 
antigen; VWF:RCo: ristocetin cofactor 
activity and VWF:CB1: type I- collagen- VWF 
binding levels; between the compound 
heterozygous proband and VWD2M 
controls with missense mutations located 
at the A1 domain. Before DDAVP infusion: 
; after DDAVP infusion: . Mutations 
in VWD2M controls: homozygous state: 
p.Arg1374Cys (pink); heterozygous state: 
p.Arg1334Gln (red); p.Arg1374Cys (green); 
p.Arg1374Leu (yellow); p.Ala1437Thr (light 
green); p.Thr1468Ile (blue). Mutations 













































































































































































     |  167WOODS et al.
performed the multimeric profile, VWF:CB1, and VWFpp assays. 
D.M. Primrose made the modeling and alignment analysis. A. N. 
Blanco was responsible for FVIII:C and VWF:Ag assays. A. Sánchez- 
Luceros was responsible of recruitment patients and the mainte-
nance of clinical records. M. A. Lazzari gave final approval of the 
version to be published. All authors have revised the draft and 
approved the final manuscript.
RELATIONSHIP DISCLOSURE
None of the authors have any disclosures relevant to this paper.
REFERENCES
 1. Fidalgo T, Oliveira A, Silva Pinto C, et al. VWF collagen (types III 
and VI)- binding defects in a cohort of type 2M VWD patients – a 
strategy for improvement of a challenging diagnosis. Haemophilia. 
2017;23:e143–7.
 2. Doruelo AL, Haberichter SL, Christopherson PA, et al. Clinical and 
laboratory phenotype variability in type 2M von Willebrand disease. J 
Thromb Haemost. 2017;15:1559–66.
 3. Rodeghiero F, Tosetto A, Abshire T, et al.; ISTH/SSC joint VWF and 
Perinatal/Pediatric Hemostasis Subcommittees Working Group. 
ISTH/SSC bleeding assessment tool: a standardized questionnaire 
and a proposal for a new bleeding score for inherited bleeding disor-
ders. J Thromb Haemost. 2010;8:2063–5.
 4. Janssen CA, Scholten PC, Heintz AP. A simple visual assessment tech-
nique to discriminate between menorrhagia and normal menstrual 
blood loss. Obstet Gynecol. 1995;85:977–82.
 5. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin. 
A simple screening test for first stage plasma clotting factor deficien-
cies. Am J Clin Pathol. 1961;36:212–9.
 6. Taylor LD. The application of the biotin- avidin system to the 
von Willebrand factor antigen immunoassay. Thromb Haemost. 
1988;59:251–4.
 7. Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson 
J. Letter: a method for assaying von Willebrand factor (ristocetin co-
factor). Thromb Diath Haemorrh. 1975;34:306–11.
 8. Borchiellini A, Fijnvandraat K, ten Cate JW, et al. Quantitative analysis 
of von Willebrand factor propeptide release in vivo: effect of exper-
imental endotoxemia and administration of 1- deamino- 8- d- arginine 
vasopressin in humans. Blood. 1996;88:2951–8.
 9. Farias C, Kempfer AC, Blanco A, Woods AI, Lazzari MA. Visualization 
of the multimeric structure of von Willebrand factor by immunoenzy-
matic stain using avidin- peroxidase complex instead of avidin- biotin 
peroxidase complex. Thromb Res. 1989;53:513–8.
 10. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin 
is influenced by the genotype and phenotype in type 1 von Willebrand 
disease (VWD): results from the European Study MCMDM- 1VWD. 
Blood. 2008;111:3531–9.
 11. Dumas JJ, Kumar R, McDonagh T, et al. Crystal structure of the wild- 
type von Willebrand factor A1- glycoprotein Ibalpha complex reveals 
conformation differences with a complex bearing von Willebrand dis-
ease mutations. J Biol Chem. 2004;279:23327–34.
 12. Jakobi AJ, Mashaghi A, Tans SJ, Huizinga EG. Calcium modulates 
force sensing by the von Willebrand factor A2 domain. Nat Commun. 
2011;2:385.
 13. Kozakov D, Hall DR, Xia B, et al. The ClusPro web server for protein- 
protein docking. Nat Protoc. 2017;12:255–78.
 14. Nielsen M, Lundegaard C, Lund O, Petersen TN. CPHmodels- 3.0 – 
remote homology modeling using structure guided sequence profiles. 
Nucleic Acids Res. 2010;38:W576–81.
 15. Laskowski RA. PDBsum: summaries and analyses of PDB structures. 
Nucleic Acids Res. 2001;29:221–2.
 16. Michiels JJ, Smejkal P, Penka M, et al. Diagnostic differentiation of 
von Willebrand disease types 1 and 2 by von Willebrand factor mul-
timer analysis and DDAVP challenge test. Clin Appl Thromb Hemost. 
2017;23:518–31.
 17. Armaroli A, Trabanelli C, Scotton C, et al. Paternal germline mo-
saicism in collagen VI related myopathies. Eur J Paediatr Neurol. 
2015;19:533–6.
 18. Pagliari MT, Baronciani L, Stufano F, et al. von Willebrand disease type 
1 mutation p.Arg1379Cys and the variant p.Ala1377Val synergisti-
cally determine a 2M phenotype in four Italian patients. Haemophilia. 
2016;22:e502–11.
 19. Hickson N, Hampshire D, Winship P, et al. MCMDM- 1VWD and 
ZPMCB- VWD study groups. von Willebrand factor variant p.Arg-
924Gln marks an allele associated with reduced von Willebrand fac-
tor and factor VIII levels. J Thromb Haemost. 2010;8:1986–93.
 20. Woods AI, Kempfer AC, Sánchez-Luceros A, Calderazzo JC, Grosso 
SH, Lazzari MA. Clinical profile of the association of p. R1205H and 
p.R924Q in a patient with von Willebrand’s disease. Haemophilia. 
2013;19:e180–1.
 21. Flood VH, Gill JC, Christopherson PA, et al. Comparison of type I, type 
III and type VI collagen binding assays in diagnosis of von Willebrand 
disease. J Thromb Haemost. 2012;10:1425–32.
 22. Ross JM, McIntire LV, Moake JL, Rand JH. Platelet adhesion and ag-
gregation on human type VI collagen surfaces under physiological 
flow conditions. Blood. 1995;85:1826–35.
 23. Larsen DM, Haberichter SL, Gill JC, Shapiro AD, Flood VH. Variability 
in platelet- and collagen- binding defects in type 2M von Willebrand 
disease. Haemophilia. 2013;19:590–4.
 24. Tischer A, Campbell JC, Machha VR, et al. Mutational constraints on 
local unfolding inhibit the rheological adaptation of von Willebrand 
factor. J Biol Chem. 2016;291:3848–59.
 25. Tischer A, Madde P, Moon-Tasson L, Auton M. Misfolding of vWF to 
pathologically disordered conformations impacts the severity of von 
Willebrand disease. Biophys J. 2014;107:1185–95.
How to cite this article: Woods AI, Paiva J, Kempfer AC, et al. 
Combined effects of two mutations in von Willebrand disease 
2M phenotype. Res Pract Thromb Haemost. 2018;2:162–167. 
https://doi.org/10.1002/rth2.12067
